Introduction: Idiopathic inflammatory myopathies (IIMs) are a group of systemic connective tissue diseases that present with muscular and extra-muscular manifestations. There are few reports on kidney involvement, especially in dermatomyositis (DM) patients. We evaluated the clinical, laboratory, capillaroscopy, and kidney pathology of patients with DM, who presented with proteinuria during the first year, and followed them for response to treatment.
Material and methods: We evaluated 205 patients with proximal muscle weakness or high muscle enzymes, who referred to the nailfold capillaroscopy clinic from April 2010 to October 2021. Seventy-four patients fulfilled the New 2017 EULAR/ACR Classification Criteria for adult and juvenile IM with probability of ≥ 90% for DM with duration of ≤ 12 months and proteinuria > 350 mg/24 hours. All manifestations of patients with glomerulopathy and their kidney biopsies were reviewed, and they were followed for their treatment response.
Results: From 74 patients with DM, 52 female and 22 male, median age 37 (19-65) years, and disease duration of median 4.5 (1-12) months, 2 (2.7%) patients (25- and 28-year-old male) had proteinuria. Their kidney biopsy showed mesangioproliferative glomerulonephritis (GN). There was no case of acute or chronic kidney damage or rhabdomyolysis. Both had high disease activity, high erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), abnormal capillaroscopy, and high anti-Ro positivity with good early response of their kidney function, muscle weakness, and laboratory tests after immunosuppressive treatment for 3-6 months. One patient had capillaroscopy follow-up, and all abnormalities were resolved in 8 fingers. One patient, due to poor follow-up, after 8 months had recurrence of his disease.
Conclusions: We found mesangioproliferative GN as a rare extra-muscular manifestation in patients with DM in the active and early phase of the disease. Full immunosuppressive treatment showed early complete recovery in these patients.
{"title":"Glomerulopathy in patients with dermatomyositis in early active disease: clinical, pathological and capillaroscopic manifestations, and response to treatment.","authors":"Saeedeh Shenavandeh, Mahsa TorabiJahromi, Sahand Mohammadzadeh","doi":"10.5114/reum.2022.117840","DOIUrl":"https://doi.org/10.5114/reum.2022.117840","url":null,"abstract":"<p><strong>Introduction: </strong>Idiopathic inflammatory myopathies (IIMs) are a group of systemic connective tissue diseases that present with muscular and extra-muscular manifestations. There are few reports on kidney involvement, especially in dermatomyositis (DM) patients. We evaluated the clinical, laboratory, capillaroscopy, and kidney pathology of patients with DM, who presented with proteinuria during the first year, and followed them for response to treatment.</p><p><strong>Material and methods: </strong>We evaluated 205 patients with proximal muscle weakness or high muscle enzymes, who referred to the nailfold capillaroscopy clinic from April 2010 to October 2021. Seventy-four patients fulfilled the New 2017 EULAR/ACR Classification Criteria for adult and juvenile IM with probability of ≥ 90% for DM with duration of ≤ 12 months and proteinuria > 350 mg/24 hours. All manifestations of patients with glomerulopathy and their kidney biopsies were reviewed, and they were followed for their treatment response.</p><p><strong>Results: </strong>From 74 patients with DM, 52 female and 22 male, median age 37 (19-65) years, and disease duration of median 4.5 (1-12) months, 2 (2.7%) patients (25- and 28-year-old male) had proteinuria. Their kidney biopsy showed mesangioproliferative glomerulonephritis (GN). There was no case of acute or chronic kidney damage or rhabdomyolysis. Both had high disease activity, high erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), abnormal capillaroscopy, and high anti-Ro positivity with good early response of their kidney function, muscle weakness, and laboratory tests after immunosuppressive treatment for 3-6 months. One patient had capillaroscopy follow-up, and all abnormalities were resolved in 8 fingers. One patient, due to poor follow-up, after 8 months had recurrence of his disease.</p><p><strong>Conclusions: </strong>We found mesangioproliferative GN as a rare extra-muscular manifestation in patients with DM in the active and early phase of the disease. Full immunosuppressive treatment showed early complete recovery in these patients.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 3","pages":"200-208"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/73/8d/RU-60-47405.PMC9301663.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40621455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-07-13DOI: 10.5114/reum.2022.117836
Hanna Dziedzic-Oleksy, Adam Mazurek, Kamil Bugała, Carlo Perricone, Leszek Drabik, Wojciech Płazak
Introduction Systemic lupus erythematosus (SLE) is characterized by early atherothrombosis. Pulse wave velocity (PWV) is a promising tool for the diagnosis of early vascular remodelling and initial atherosclerotic plaque formation. Our objective was to evaluate PWV and its relationship with coronary atherosclerosis and thrombotic biomarkers in patients with SLE. Material and methods In 26 patients with SLE with stable clinical conditions, mean age of 39.1 ±11.7 years and without a history of coronary artery disease, multidetector computed tomography (MDCT)-based coronary calcium scoring (CACS) was performed and PWV measured. Laboratory evaluation included serum levels of anticardiolipin and anti-β2-glycoprotein antibodies (anti-β2-GPI), lupus anticoagulant (LA), D-dimers, thrombin–antithrombin complexes (TAT), and von Willebrand factor (vWF). Results Multidetector computed tomography revealed coronary calcifications in 8 (30.8%) patients and the median CACS was 52.4 HU (range 2–843.2). The mean PWV was 9.0 ±3.2 m/s and was higher in patients aged > 50 years (+33.7% vs. < 50 years), those with positive LA (+28.2% vs. LA negative), TAT ≥ 10 μg/l (+18.1% vs. < 10 μg/l), vWF ≥ 200 IU/dl (+51.8% vs. < 200 IU/dl) and with coronary atherosclerosis (CACS > 0; +21.4% vs. CACS = 0). In contrast, the duration of the disease, D-dimers, anticardiolipin, and anti-β2-GPI antibodies did not influence PWV. In the group without atherosclerosis (CACS = 0, n =18), patients with vWF ≥ 200 IU/dl had a 19.3% higher PWV compared to the rest. Conclusions In patients with SLE, PWV was associated with the presence of coronary atherosclerotic lesions in MDCT. Furthermore, arterial stiffness was higher in patients with markers of endothelial dysfunction and a prothrombotic state, suggesting their contribution to the early stages of arterial remodelling in SLE.
系统性红斑狼疮(SLE)以早期动脉粥样硬化血栓形成为特征。脉搏波速度(PWV)是诊断早期血管重构和动脉粥样硬化斑块形成的一种很有前途的工具。我们的目的是评估SLE患者的PWV及其与冠状动脉粥样硬化和血栓形成生物标志物的关系。材料与方法:对26例临床状况稳定、平均年龄39.1±11.7岁、无冠状动脉疾病史的SLE患者进行基于多探测器计算机断层扫描(MDCT)的冠状动脉钙化评分(CACS)并测量PWV。实验室评估包括血清抗心磷脂和抗β2-糖蛋白抗体(anti-β2-GPI)、狼疮抗凝血剂(LA)、d -二聚体、凝血酶-抗凝血酶复合物(TAT)和血管性血友病因子(vWF)水平。结果:多探测器计算机断层扫描显示8例(30.8%)患者冠状动脉钙化,中位CACS为52.4 HU(范围2-843.2)。平均PWV为9.0±3.2 m/s,年龄> 50岁(+33.7% vs. < 50岁)、LA阳性(+28.2% vs. LA阴性)、TAT≥10 μg/l (+18.1% vs. < 10 μg/l)、vWF≥200 IU/dl (+51.8% vs. < 200 IU/dl)、冠状动脉粥样硬化(CACS > 0;相比之下,病程、d -二聚体、抗心磷脂和抗β2- gpi抗体对PWV没有影响。在无动脉粥样硬化组(CACS = 0, n =18)中,vWF≥200 IU/dl的患者的PWV比其他患者高19.3%。结论:在SLE患者中,PWV与MDCT中冠状动脉粥样硬化病变的存在有关。此外,在内皮功能障碍和血栓前状态的患者中,动脉僵硬度更高,这表明它们对SLE早期动脉重构的贡献。
{"title":"Arterial stiffness and atherosclerosis in systemic lupus erythematosus patients.","authors":"Hanna Dziedzic-Oleksy, Adam Mazurek, Kamil Bugała, Carlo Perricone, Leszek Drabik, Wojciech Płazak","doi":"10.5114/reum.2022.117836","DOIUrl":"https://doi.org/10.5114/reum.2022.117836","url":null,"abstract":"Introduction Systemic lupus erythematosus (SLE) is characterized by early atherothrombosis. Pulse wave velocity (PWV) is a promising tool for the diagnosis of early vascular remodelling and initial atherosclerotic plaque formation. Our objective was to evaluate PWV and its relationship with coronary atherosclerosis and thrombotic biomarkers in patients with SLE. Material and methods In 26 patients with SLE with stable clinical conditions, mean age of 39.1 ±11.7 years and without a history of coronary artery disease, multidetector computed tomography (MDCT)-based coronary calcium scoring (CACS) was performed and PWV measured. Laboratory evaluation included serum levels of anticardiolipin and anti-β2-glycoprotein antibodies (anti-β2-GPI), lupus anticoagulant (LA), D-dimers, thrombin–antithrombin complexes (TAT), and von Willebrand factor (vWF). Results Multidetector computed tomography revealed coronary calcifications in 8 (30.8%) patients and the median CACS was 52.4 HU (range 2–843.2). The mean PWV was 9.0 ±3.2 m/s and was higher in patients aged > 50 years (+33.7% vs. < 50 years), those with positive LA (+28.2% vs. LA negative), TAT ≥ 10 μg/l (+18.1% vs. < 10 μg/l), vWF ≥ 200 IU/dl (+51.8% vs. < 200 IU/dl) and with coronary atherosclerosis (CACS > 0; +21.4% vs. CACS = 0). In contrast, the duration of the disease, D-dimers, anticardiolipin, and anti-β2-GPI antibodies did not influence PWV. In the group without atherosclerosis (CACS = 0, n =18), patients with vWF ≥ 200 IU/dl had a 19.3% higher PWV compared to the rest. Conclusions In patients with SLE, PWV was associated with the presence of coronary atherosclerotic lesions in MDCT. Furthermore, arterial stiffness was higher in patients with markers of endothelial dysfunction and a prothrombotic state, suggesting their contribution to the early stages of arterial remodelling in SLE.","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 3","pages":"165-172"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/47/RU-60-47401.PMC9301661.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40622961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inroduction: The results of experimental and clinical studies in recent years indicate that the transplantation of multipotent mesenchymal stromal cells (MMSCs) is a possible approach for the "restoration" of the immune system of patients with autoimmune diseases, in particular, rheumatoid arthritis. However, the strength and duration of the effect vary greatly, which indicates incomplete correction of the tested parameters, thereby opening up the prospect of improving this method of treatment by choosing dose-time parameters and methods of their administration. The aim of this research was to determine the indices of cellular immunity in animals with adjuvant arthritis and therapy with cryopreserved MMSCs derived from adipose and cartilage tissues.
Material and methods: Adjuvant arthritis in male rats was modeled by subplantar administration of Freund's complete adjuvant. On day 7 of modeling, experimental animals were administered with saline (control group) or cryopreserved MMSCs from adipose or cartilaginous tissue locally or generalized. On day 28 after therapy the body weight, spleen index and cellularity, and content of CD3+, CD4+, CD8+, CD4+CD25+ cells in the spleen were determined.
Results: In the control group of animals, the inflammation was pronounced, as evidenced by a significant increase in the studied parameters throughout the observation period. The use of cryopreserved MMSCs from adipose and cartilaginous tissues led to the restoration of T regulatory cells (Treg) on day 28. Generalized administration of cells had a more pronounced therapeutic effect compared to the animals with local administration. These data can be used to justify and develop a therapeutic approach to rheumatoid arthritis in clinical practice.
Conclusions: Cell therapy with cryopreserved MMSCs from investigated sources provided by both local and generalized administration to animals with adjuvant arthritis has a correcting effect on the cellular immunity.
{"title":"Role of cryopreserved multipotent mesenchymal stromal cells in modulation of some indices of cell immunity in adjuvant arthritis.","authors":"Dmytro Vvedenskyi, Nataliia Volkova, Natalya Babenko, Yulia Gaevska, Mariia Yukhta, Anatoliy Goltsev","doi":"10.5114/reum.2022.117842","DOIUrl":"https://doi.org/10.5114/reum.2022.117842","url":null,"abstract":"<p><strong>Inroduction: </strong>The results of experimental and clinical studies in recent years indicate that the transplantation of multipotent mesenchymal stromal cells (MMSCs) is a possible approach for the \"restoration\" of the immune system of patients with autoimmune diseases, in particular, rheumatoid arthritis. However, the strength and duration of the effect vary greatly, which indicates incomplete correction of the tested parameters, thereby opening up the prospect of improving this method of treatment by choosing dose-time parameters and methods of their administration. The aim of this research was to determine the indices of cellular immunity in animals with adjuvant arthritis and therapy with cryopreserved MMSCs derived from adipose and cartilage tissues.</p><p><strong>Material and methods: </strong>Adjuvant arthritis in male rats was modeled by subplantar administration of Freund's complete adjuvant. On day 7 of modeling, experimental animals were administered with saline (control group) or cryopreserved MMSCs from adipose or cartilaginous tissue locally or generalized. On day 28 after therapy the body weight, spleen index and cellularity, and content of CD3+, CD4+, CD8+, CD4+CD25+ cells in the spleen were determined.</p><p><strong>Results: </strong>In the control group of animals, the inflammation was pronounced, as evidenced by a significant increase in the studied parameters throughout the observation period. The use of cryopreserved MMSCs from adipose and cartilaginous tissues led to the restoration of T regulatory cells (Treg) on day 28. Generalized administration of cells had a more pronounced therapeutic effect compared to the animals with local administration. These data can be used to justify and develop a therapeutic approach to rheumatoid arthritis in clinical practice.</p><p><strong>Conclusions: </strong>Cell therapy with cryopreserved MMSCs from investigated sources provided by both local and generalized administration to animals with adjuvant arthritis has a correcting effect on the cellular immunity.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 3","pages":"213-219"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/25/RU-60-47407.PMC9301669.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40622962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-11-04DOI: 10.5114/reum.2022.120756
Suhel Gabriele Al Khayyat, Roberto D'Alessandro, Edoardo Conticini, Serena Pierguidi, Paolo Falsetti, Caterina Baldi, Marco Bardelli, Stefano Gentileschi, Antonella Nicosia, Bruno Frediani
Introduction: Bone loss is a common feature in several autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis (RA). Indeed, the high levels of pro-inflammatory cytokines seem to enhance bone resorption and to diminish bone formation, thus producing an uncoupling between osteoclast and osteoblast function and favoring the onset of juxtarticular as well as systemic osteoporosis. Many papers underline the high prevalence of osteoporosis in RA, as well as the negative correlation between interleukin 6 (IL-6) serum levels and bone mineral density (BMD). The aim of this study was to assess the effectiveness of one-year treatment with tocilizumab (TCZ), the first approved IL-6 receptor inhibitor, in reducing bone loss in RA.
Material and methods: We enrolled 18 patients fulfilling 2010 ACR and EULAR criteria for RA from our arthritis outpatient clinic, assessing clinical and biochemical parameters during a 12-month period. The patients received TCZ 8 mg/kg i.v. every 4 weeks and underwent dual energy X-ray absorptiometry (DXA) for the measurement of bone mineral density (BMD) at baseline and at the end of study. Serum levels of C-reactive protein (CRP), erythrocytes sedimentation rate (ESR), IL-6, serum CrossLaps, osteoprotegerin (OPG), receptor activator of nuclear factor κβ ligand (RANK-L) and dickkopf-1 (DKK-1) were measured at baseline, at 6 months and 1 year.
Results: No significant difference in IL-6, RANK-L, DKK-1, OPG and serum CrossLaps levels between baseline, 6 months and 1 year were found. A significant increase of lumbar spine BMD was evidenced after 1 year of TCZ treatment. No difference in total body and femoral neck BMD was documented the end of the study.
Conclusions: This study suggest the bone-sparing effect of TCZ in RA affected individuals.
{"title":"Bone-sparing effects of tocilizumab in rheumatoid arthritis: a monocentric observational study.","authors":"Suhel Gabriele Al Khayyat, Roberto D'Alessandro, Edoardo Conticini, Serena Pierguidi, Paolo Falsetti, Caterina Baldi, Marco Bardelli, Stefano Gentileschi, Antonella Nicosia, Bruno Frediani","doi":"10.5114/reum.2022.120756","DOIUrl":"https://doi.org/10.5114/reum.2022.120756","url":null,"abstract":"<p><strong>Introduction: </strong>Bone loss is a common feature in several autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis (RA). Indeed, the high levels of pro-inflammatory cytokines seem to enhance bone resorption and to diminish bone formation, thus producing an uncoupling between osteoclast and osteoblast function and favoring the onset of juxtarticular as well as systemic osteoporosis. Many papers underline the high prevalence of osteoporosis in RA, as well as the negative correlation between interleukin 6 (IL-6) serum levels and bone mineral density (BMD). The aim of this study was to assess the effectiveness of one-year treatment with tocilizumab (TCZ), the first approved IL-6 receptor inhibitor, in reducing bone loss in RA.</p><p><strong>Material and methods: </strong>We enrolled 18 patients fulfilling 2010 ACR and EULAR criteria for RA from our arthritis outpatient clinic, assessing clinical and biochemical parameters during a 12-month period. The patients received TCZ 8 mg/kg <i>i.v</i>. every 4 weeks and underwent dual energy X-ray absorptiometry (DXA) for the measurement of bone mineral density (BMD) at baseline and at the end of study. Serum levels of C-reactive protein (CRP), erythrocytes sedimentation rate (ESR), IL-6, serum CrossLaps, osteoprotegerin (OPG), receptor activator of nuclear factor κβ ligand (RANK-L) and dickkopf-1 (DKK-1) were measured at baseline, at 6 months and 1 year.</p><p><strong>Results: </strong>No significant difference in IL-6, RANK-L, DKK-1, OPG and serum CrossLaps levels between baseline, 6 months and 1 year were found. A significant increase of lumbar spine BMD was evidenced after 1 year of TCZ treatment. No difference in total body and femoral neck BMD was documented the end of the study.</p><p><strong>Conclusions: </strong>This study suggest the bone-sparing effect of TCZ in RA affected individuals.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 5","pages":"326-331"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/01/RU-60-48072.PMC9661410.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-05-18DOI: 10.5114/reum.2022.115988
Brygida Kwiatkowska
In Poland the National Consultants for the Ministry of Health operate in the fields of health care associated with medical specialties they represent. They are appointed by the Minister of Health from among specialists in the fields of medicine, pharmaceutics and other disciplines which find application in health management [1]. Primary tasks of the National Consultants include initiating national epidemiological research, assessment of methods and results of such research and forecasting health needs with the use of the obtained results. National Consultants advise on the creation of government health care programs, including the National Health Program. They also evaluate patients’ applications for receiving treatment or diagnostic services abroad. Finally, they play an important role in the system of training of medical specialists, advising on the tasks fulfilled by the Centre for Medical Exams, the Centre of Medical Postgraduate Education and the Centre of Medical Postgraduate Education for Nurses and Midwives. Each National Consultant is chosen for a 5-year term. In May 2021 I was appointed to the post of National Consultant in the field of rheumatology. As in 2021 the COVID-19 pandemic continued, the ongoing struggle with this virus affected the availability of the rheumatologic care for patients. In this situation my activity concentrated initially on the identification of the most pressing problems faced by rheumatologists and health care managers. In order to obtain the proper knowledge in this respect, I turned to the Provincial Consultants, asking them to prepare reports on the availability of rheumatologic care in the particular provinces of Poland. On my request, experts in the field of rheumatology, possessing both clinical and scientific experience alike – Prof. Maria Majdan, Prof. Joanna Makowska, Maria Maślińska PhD and the director of the National Institute of Geriatrics, Rheumatology and Rehabilitation Marek Tombarkiewicz PhD (a health care manager and a medical doctor) – prepared, along with myself, the “Opening report” of the National Consultant in the field of rheumatology, intended both as a review of the state of affairs existing at the beginning of my term in office and as a plan of action for the years to come [2]. The priority targets for the National Consultant are defined as: the improvement of the hospital and ambulatory rheumatic care availability in the time of the COVID-19 pandemic and the curtailment of the delays in the diagnosis of rheumatic diseases though the introduction of so-called complex care for patients with early arthritis. The complex care project was previously presented and submitted to the Ministry of Health [3]. It will also be vital to establish a network of medical centres for patients most diagnostically challenging and requiring the most advanced treatments. Such centres should co-operate closely with other rheumatologic facilities of lower health care levels, as well as other high-level cen
{"title":"Opening report of the Polish National Consultant in the field of rheumatology.","authors":"Brygida Kwiatkowska","doi":"10.5114/reum.2022.115988","DOIUrl":"https://doi.org/10.5114/reum.2022.115988","url":null,"abstract":"In Poland the National Consultants for the Ministry of Health operate in the fields of health care associated with medical specialties they represent. They are appointed by the Minister of Health from among specialists in the fields of medicine, pharmaceutics and other disciplines which find application in health management [1]. Primary tasks of the National Consultants include initiating national epidemiological research, assessment of methods and results of such research and forecasting health needs with the use of the obtained results. National Consultants advise on the creation of government health care programs, including the National Health Program. They also evaluate patients’ applications for receiving treatment or diagnostic services abroad. Finally, they play an important role in the system of training of medical specialists, advising on the tasks fulfilled by the Centre for Medical Exams, the Centre of Medical Postgraduate Education and the Centre of Medical Postgraduate Education for Nurses and Midwives. Each National Consultant is chosen for a 5-year term. In May 2021 I was appointed to the post of National Consultant in the field of rheumatology. As in 2021 the COVID-19 pandemic continued, the ongoing struggle with this virus affected the availability of the rheumatologic care for patients. In this situation my activity concentrated initially on the identification of the most pressing problems faced by rheumatologists and health care managers. In order to obtain the proper knowledge in this respect, I turned to the Provincial Consultants, asking them to prepare reports on the availability of rheumatologic care in the particular provinces of Poland. On my request, experts in the field of rheumatology, possessing both clinical and scientific experience alike – Prof. Maria Majdan, Prof. Joanna Makowska, Maria Maślińska PhD and the director of the National Institute of Geriatrics, Rheumatology and Rehabilitation Marek Tombarkiewicz PhD (a health care manager and a medical doctor) – prepared, along with myself, the “Opening report” of the National Consultant in the field of rheumatology, intended both as a review of the state of affairs existing at the beginning of my term in office and as a plan of action for the years to come [2]. The priority targets for the National Consultant are defined as: the improvement of the hospital and ambulatory rheumatic care availability in the time of the COVID-19 pandemic and the curtailment of the delays in the diagnosis of rheumatic diseases though the introduction of so-called complex care for patients with early arthritis. The complex care project was previously presented and submitted to the Ministry of Health [3]. It will also be vital to establish a network of medical centres for patients most diagnostically challenging and requiring the most advanced treatments. Such centres should co-operate closely with other rheumatologic facilities of lower health care levels, as well as other high-level cen","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 2","pages":"79-80"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/82/RU-60-46974.PMC9238306.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40556407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-05-18DOI: 10.5114/reum.2022.115664
Karolina Nowak, Olga Gumkowska-Sroka, Przemysław Kotyla
Systemic lupus erythematosus is a connective disease in which all vitally important organs may be affected. The etiology of the disease is largely unknown and almost all immunological mechanisms have been proposed as the pathophysiological background of the disease. Among them, endothelial damage and dysfunction seem to play a pivotal role. Endothelial damage can be accurately measured using adhesion molecules such asintercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), platelet endothelial cell adhesion molecule (PECAM) and selectins. In this review we discuss the role of well-known cellular adhesion molecules as pathogenic factors in disease development as well as disease activity biomarkers.
{"title":"Adhesion molecules: a way to understand lupus.","authors":"Karolina Nowak, Olga Gumkowska-Sroka, Przemysław Kotyla","doi":"10.5114/reum.2022.115664","DOIUrl":"https://doi.org/10.5114/reum.2022.115664","url":null,"abstract":"<p><p>Systemic lupus erythematosus is a connective disease in which all vitally important organs may be affected. The etiology of the disease is largely unknown and almost all immunological mechanisms have been proposed as the pathophysiological background of the disease. Among them, endothelial damage and dysfunction seem to play a pivotal role. Endothelial damage can be accurately measured using adhesion molecules such asintercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), platelet endothelial cell adhesion molecule (PECAM) and selectins. In this review we discuss the role of well-known cellular adhesion molecules as pathogenic factors in disease development as well as disease activity biomarkers.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 2","pages":"133-141"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/20/f3/RU-60-46888.PMC9238314.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40556408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-07-13DOI: 10.5114/reum.2022.117844
Łukasz Pulik, Krzysztof Romaniuk, Nicola Dyrek, Nina Grabowska, Paweł Łęgosz
Total hip arthroplasty (THA) is one of the most frequent orthopedic procedures worldwide and its surgical volume is constantly growing. To address the patients' restricted access to healthcare resources and limited one-on-one contact with the surgeon during the COVID-19 pandemic, we created a reliable source of information for patients undergoing THA. The use of mHealth is increasing with access to modern technology in Poland. Information related to health issues is the second most common web search performed by older adults. Our project aimed to create the first Polish mobile application for THA patients: Endopedia. Endopedia was developed for the Android platform based on a survey performed among patients and a collection of frequently asked questions on patients' internet forums. The content was adapted to the elderly and visually impaired requirements. mHealth solutions should not replace one-on-one conversation, but they can provide substantial support for patients in conditions of limited information.
{"title":"First Polish mobile application for patients undergoing total hip arthroplasty.","authors":"Łukasz Pulik, Krzysztof Romaniuk, Nicola Dyrek, Nina Grabowska, Paweł Łęgosz","doi":"10.5114/reum.2022.117844","DOIUrl":"10.5114/reum.2022.117844","url":null,"abstract":"<p><p>Total hip arthroplasty (THA) is one of the most frequent orthopedic procedures worldwide and its surgical volume is constantly growing. To address the patients' restricted access to healthcare resources and limited one-on-one contact with the surgeon during the COVID-19 pandemic, we created a reliable source of information for patients undergoing THA. The use of mHealth is increasing with access to modern technology in Poland. Information related to health issues is the second most common web search performed by older adults. Our project aimed to create the first Polish mobile application for THA patients: Endopedia. Endopedia was developed for the Android platform based on a survey performed among patients and a collection of frequently asked questions on patients' internet forums. The content was adapted to the elderly and visually impaired requirements. mHealth solutions should not replace one-on-one conversation, but they can provide substantial support for patients in conditions of limited information.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 3","pages":"224-227"},"PeriodicalIF":1.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/ed/RU-60-47409.PMC9301662.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40621458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-07-13DOI: 10.5114/reum.2022.117839
Yany Magali Chamorro-Melo, Omar-Javier Calixto, Juan Manuel Bello-Gualtero, Wilson Bautista-Molano, Adriana Beltran-Ostos, Consuelo Romero-Sánchez
Introduction: Adipokines may play a role in the early stages of rheumatoid arthritis. This study evaluated the performance of adipokines in a Colombian population with early rheumatoid arthritis and its relationship with disease activity.
Material and methods: A cross-sectional study evaluated serum adipokine levels (adiponectin, resistin, adipsin, vaspin, and leptin) in patients with early rheumatoid arthritis (eRA), evaluating demographic and clinical variables, along with a control group matched by age and gender. A factorial analysis was performed using principal components analysis (PCA), and a Spearman correlation analysis was performed. Similarly, a cut-off point for serum levels is proposed based on the receiver operating characteristic (ROC) curve between eRA and controls and sensitivity analysis.
Results: Fifty-one eRA subjects were included; there were 41 women. The body mass index (BMI) was 25.12 ±3.8. A statistically significant correlation was identified between adipsin, BMI, and RAPID3. Vaspin and leptin were correlated with BMI. Resistin levels were higher in patients with RAPID3 near remission (p = 0.041), and adiponectin, vaspin, and leptin levels were lower in patients with DAS28 ESR in remission (p = 0.033, p = 0.012, and p = 0.017, respectively). Principal components analysis in component 1 adipokines as adipsin and leptin with BMI and RAPID3 as disease activity index are grouped. Moreover, component 2 had a strong relation between ESR and CRP with an inverse correlation with cholesterol levels and vaspin. A cut-off point was established for each adipokine, thus identifying the best performance for leptin levels greater than 0.58 ng/ml with a sensitivity of 76.5% and specificity of 74.5%.
Conclusions: Adipokine levels are relevant in eRA, especially with disease activity indexes. Resistin levels were higher in patients with an activity index near remission. Otherwise, adiponectin, vaspin, and leptin levels were lower in patients with low activity indexes. RAPID3 correlated with adipsin. It is complementary to the previously published analysis of adipokines.
{"title":"Evaluation of the adipokine profile (adiponectin, resistin, adipsin, vaspin, and leptin) in patients with early rheumatoid arthritis and its correlation with disease activity.","authors":"Yany Magali Chamorro-Melo, Omar-Javier Calixto, Juan Manuel Bello-Gualtero, Wilson Bautista-Molano, Adriana Beltran-Ostos, Consuelo Romero-Sánchez","doi":"10.5114/reum.2022.117839","DOIUrl":"https://doi.org/10.5114/reum.2022.117839","url":null,"abstract":"<p><strong>Introduction: </strong>Adipokines may play a role in the early stages of rheumatoid arthritis. This study evaluated the performance of adipokines in a Colombian population with early rheumatoid arthritis and its relationship with disease activity.</p><p><strong>Material and methods: </strong>A cross-sectional study evaluated serum adipokine levels (adiponectin, resistin, adipsin, vaspin, and leptin) in patients with early rheumatoid arthritis (eRA), evaluating demographic and clinical variables, along with a control group matched by age and gender. A factorial analysis was performed using principal components analysis (PCA), and a Spearman correlation analysis was performed. Similarly, a cut-off point for serum levels is proposed based on the receiver operating characteristic (ROC) curve between eRA and controls and sensitivity analysis.</p><p><strong>Results: </strong>Fifty-one eRA subjects were included; there were 41 women. The body mass index (BMI) was 25.12 ±3.8. A statistically significant correlation was identified between adipsin, BMI, and RAPID3. Vaspin and leptin were correlated with BMI. Resistin levels were higher in patients with RAPID3 near remission (<i>p</i> = 0.041), and adiponectin, vaspin, and leptin levels were lower in patients with DAS28 ESR in remission (<i>p</i> = 0.033, <i>p</i> = 0.012, and <i>p</i> = 0.017, respectively). Principal components analysis in component 1 adipokines as adipsin and leptin with BMI and RAPID3 as disease activity index are grouped. Moreover, component 2 had a strong relation between ESR and CRP with an inverse correlation with cholesterol levels and vaspin. A cut-off point was established for each adipokine, thus identifying the best performance for leptin levels greater than 0.58 ng/ml with a sensitivity of 76.5% and specificity of 74.5%.</p><p><strong>Conclusions: </strong>Adipokine levels are relevant in eRA, especially with disease activity indexes. Resistin levels were higher in patients with an activity index near remission. Otherwise, adiponectin, vaspin, and leptin levels were lower in patients with low activity indexes. RAPID3 correlated with adipsin. It is complementary to the previously published analysis of adipokines.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 3","pages":"192-199"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/e3/RU-60-47404.PMC9301668.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40622963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Pregnancy in patients with autoimmune disorders is associated with an increased risk of adverse outcomes. Sjögren's syndrome (SS) is one of the most common among autoimmune diseases. Presently data regarding the impact of SS on obstetric outcomes are scarce and inconclusive. This study aims to evaluate the impact of SS on maternal-fetal and neonatal outcomes compared with pregnancy outcomes in the general population.
Material and methods: A retrospective case-control study included 26 pregnancies in SS patients and a healthy control group (CG), followed in a Portuguese tertiary center, between 2015 and 2020. Baseline maternal data were collected, and maternal-fetal and neonatal outcomes were evaluated. Statistical analysis used SPSS 25.0, and a p-value of 0.05 was considered statistically significant.
Results: All pregnancies occurred after the diagnosis of SS, with a mean exposure time between diagnosis and pregnancy of 4.92 ±2.78 years. In the SS group, the incidence of ANA, anti-Ro/SSA, and anti-La/SSB antibodies positivity was 80.8%, 61.5%, and 46.2%, respectively. Hydroxychloroquine (HCQ) was used in 57.7%.Miscarriage was significantly higher in the SS group (19.2% vs. 1.8%, p < 0.01). There was a higher prevalence of fetal growth restriction (OR 11.16, 95% CI: 0.96-129.26). Preterm delivery (9.5% vs. 5.6%, p = 0.503) and mean birth weight (2998.16 g vs. 3155.79 g, p = 0.178) did not differ significantly between the groups. In the SS group, admission to the neonatal intensive care unit (NICU) rate was increased (OR 71.67, 95% CI: 3.78-1357.16). Three pregnancies were complicated by congenital heart block (CHB) (14.3% vs. 0%, p = 0.015). In all cases, the diagnosis was performed during second trimester of pregnancy, and betamethasone was administered.
Conclusions: Women with SS had a significantly higher incidence of miscarriage, admission to NICU, and CHB than controls. Congenital heart block was the most critical condition that affects the offspring of mothers with SS. Successful pregnancy in the study group was possible with prenatal monitoring and a multidisciplinary approach.
自身免疫性疾病患者的妊娠与不良结局的风险增加相关。Sjögren综合征(SS)是最常见的自身免疫性疾病之一。目前,关于SS对产科结果影响的数据很少且不确定。本研究旨在评估SS对母胎和新生儿结局的影响,并将其与普通人群的妊娠结局进行比较。材料和方法:一项回顾性病例对照研究,包括2015年至2020年在葡萄牙三级中心随访的26例妊娠SS患者和健康对照组(CG)。收集基线产妇数据,评估母胎和新生儿结局。统计学分析采用SPSS 25.0, p值为0.05认为有统计学意义。结果:所有妊娠均发生在SS诊断后,从诊断到妊娠平均暴露时间为4.92±2.78年。SS组ANA阳性率为80.8%,抗ro /SSA阳性率为61.5%,抗la /SSB阳性率为46.2%。羟氯喹(HCQ)占57.7%。SS组流产率明显高于对照组(19.2% vs. 1.8%, p < 0.01)。胎儿生长受限的患病率较高(OR 11.16, 95% CI: 0.96-129.26)。早产(9.5% vs. 5.6%, p = 0.503)和平均出生体重(2998.16 g vs. 3155.79 g, p = 0.178)组间无显著差异。SS组新生儿重症监护病房(NICU)入院率增加(OR 71.67, 95% CI: 3.78 ~ 1357.16)。3例妊娠合并先天性心脏传导阻滞(CHB) (14.3% vs. 0%, p = 0.015)。在所有病例中,诊断是在妊娠中期进行的,并给予倍他米松。结论:SS患者流产、入住NICU和CHB的发生率明显高于对照组。先天性心脏传导阻滞是影响SS母亲后代的最关键条件。通过产前监测和多学科方法,研究组的成功妊娠是可能的。
{"title":"Sjögren's syndrome and pregnancy: a Portuguese case-control study.","authors":"Tânia Barros, Jorge Braga, Maria Inês Abreu, Mariana Brandão, Fátima Farinha, António Marinho, António Braga","doi":"10.5114/reum.2022.120754","DOIUrl":"https://doi.org/10.5114/reum.2022.120754","url":null,"abstract":"<p><strong>Introduction: </strong>Pregnancy in patients with autoimmune disorders is associated with an increased risk of adverse outcomes. Sjögren's syndrome (SS) is one of the most common among autoimmune diseases. Presently data regarding the impact of SS on obstetric outcomes are scarce and inconclusive. This study aims to evaluate the impact of SS on maternal-fetal and neonatal outcomes compared with pregnancy outcomes in the general population.</p><p><strong>Material and methods: </strong>A retrospective case-control study included 26 pregnancies in SS patients and a healthy control group (CG), followed in a Portuguese tertiary center, between 2015 and 2020. Baseline maternal data were collected, and maternal-fetal and neonatal outcomes were evaluated. Statistical analysis used SPSS 25.0, and a <i>p</i>-value of 0.05 was considered statistically significant.</p><p><strong>Results: </strong>All pregnancies occurred after the diagnosis of SS, with a mean exposure time between diagnosis and pregnancy of 4.92 ±2.78 years. In the SS group, the incidence of ANA, anti-Ro/SSA, and anti-La/SSB antibodies positivity was 80.8%, 61.5%, and 46.2%, respectively. Hydroxychloroquine (HCQ) was used in 57.7%.Miscarriage was significantly higher in the SS group (19.2% vs. 1.8%, <i>p</i> < 0.01). There was a higher prevalence of fetal growth restriction (OR 11.16, 95% CI: 0.96-129.26). Preterm delivery (9.5% vs. 5.6%, <i>p</i> = 0.503) and mean birth weight (2998.16 g vs. 3155.79 g, <i>p</i> = 0.178) did not differ significantly between the groups. In the SS group, admission to the neonatal intensive care unit (NICU) rate was increased (OR 71.67, 95% CI: 3.78-1357.16). Three pregnancies were complicated by congenital heart block (CHB) (14.3% vs. 0%, <i>p</i> = 0.015). In all cases, the diagnosis was performed during second trimester of pregnancy, and betamethasone was administered.</p><p><strong>Conclusions: </strong>Women with SS had a significantly higher incidence of miscarriage, admission to NICU, and CHB than controls. Congenital heart block was the most critical condition that affects the offspring of mothers with SS. Successful pregnancy in the study group was possible with prenatal monitoring and a multidisciplinary approach.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 5","pages":"311-317"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/5b/RU-60-48070.PMC9661414.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-05-18DOI: 10.5114/reum.2022.116198
Piotr Tederko, Victoria Perovic-Kaczmarek, Robert Gasik, Beata Tarnacka
Background: Occipital pressure sores (OPS) are complications of the use of cervical collars. Prophylaxis of OPS in patients after cervical spinal surgery (CCS) appears to be neglected.
Material and methods: Cochrane Central, EMBASE, PubMed, SCOPUS, and Web of Science databases were searched for studies on OPS after CCS.
Results: We present the case of a patient with rheumatic arthritis who was secured with a hard collar after revision CCS and was not seen by a health professional due to the COVID-19 outbreak. The result was an OPS leading to deep tissue infection. The patient required a prolonged hospital stay and long-term antibiotic therapy. We found a lack of literature on OPS prevention in patients after CCS.
Conclusions: Patients with rheumatoid arthritis using collars after CCS are at risk of OPS. Protocols of prevention of OPS should be reviewed with respect to challenges resulting from epidemiological restrictions and accessibility of telemedical technologies.
背景:枕部压疮(OPS)是颈套使用后的并发症。预防OPS的患者后颈椎手术(CCS)似乎被忽视。材料和方法:检索Cochrane Central、EMBASE、PubMed、SCOPUS和Web of Science数据库,检索CCS后OPS的相关研究。结果:我们报告了一例风湿性关节炎患者,他在CCS翻修后用硬项圈固定,但由于COVID-19爆发而没有得到卫生专业人员的检查。结果是OPS导致深部组织感染。患者需要延长住院时间和长期抗生素治疗。我们发现缺乏关于CCS后患者OPS预防的文献。结论:类风湿关节炎患者在CCS后使用项圈有发生OPS的风险。针对流行病限制和远程医疗技术的可及性所带来的挑战,应审查项目事务处预防议定书。
{"title":"Prophylaxis of occipital pressure sores in patients after elective spinal surgery in a pandemic condition.","authors":"Piotr Tederko, Victoria Perovic-Kaczmarek, Robert Gasik, Beata Tarnacka","doi":"10.5114/reum.2022.116198","DOIUrl":"https://doi.org/10.5114/reum.2022.116198","url":null,"abstract":"<p><strong>Background: </strong>Occipital pressure sores (OPS) are complications of the use of cervical collars. Prophylaxis of OPS in patients after cervical spinal surgery (CCS) appears to be neglected.</p><p><strong>Material and methods: </strong>Cochrane Central, EMBASE, PubMed, SCOPUS, and Web of Science databases were searched for studies on OPS after CCS.</p><p><strong>Results: </strong>We present the case of a patient with rheumatic arthritis who was secured with a hard collar after revision CCS and was not seen by a health professional due to the COVID-19 outbreak. The result was an OPS leading to deep tissue infection. The patient required a prolonged hospital stay and long-term antibiotic therapy. We found a lack of literature on OPS prevention in patients after CCS.</p><p><strong>Conclusions: </strong>Patients with rheumatoid arthritis using collars after CCS are at risk of OPS. Protocols of prevention of OPS should be reviewed with respect to challenges resulting from epidemiological restrictions and accessibility of telemedical technologies.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"60 2","pages":"153-160"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/76/RU-60-47016.PMC9238308.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40558368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}